Author

Shurong Zhou

University of Michigan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:CRISPR screen· 1 Approach:deep learning· 1 Assay:proteomics· 1

Frequent Co-Authors

Guizhi ZhuiD· 2 shared Bo WeniD· 1 shared Chunpeng Yang· 1 shared Duxin SuniD· 1 shared Furong ChengiD· 1 shared Guolan Xiao· 1 shared Hanning Wen· 1 shared Jie XuiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

Guizhi ZhuORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Engineering circular guide RNA and CRISPR-Cas13d-encoding mRNA for the RNA editing of Adar1 in triple-negative breast cancer immunotherapy

Shurong Zhou, Suling Yang, Jie Xu, Guizhi Zhu

This study develops circular guide RNAs (cgRNAs) and Cas13d-encoding mRNA for efficient RNA editing of Adar1 in triple-negative breast cancer, showing improved stability and therapeutic efficacy.

bioRxiv · Jul 22, 2025 · PreprintBioengineering

Proteolysis-targeting vaccines (PROTAVs) for robust combination immunotherapy of melanoma

Qiyan Wang, Ting Su, Furong Cheng, Shurong Zhou, Xiang Liu, Mi Wang, You Xu, Ri Tang, Shimiao Liao, Jordan M. Dailey, Guolan Xiao, Chunpeng Yang, Hanning Wen, Weijia Zheng, Bo Wen, , Guizhi Zhu

This paper introduces PROTAVs, a new vaccine strategy that enhances T cell responses and combination immunotherapy for melanoma by improving antigen processing and cross-presentation.

bioRxiv · Oct 1, 2024 · PreprintBioengineering